|
|
||||||||
From Los Angeles, CA (M.E.B.); Department of Medical Genetics (J.M.F.), University of British Columbia, Vancouver, British Columbia, Canada; and Academic Department of Medical Genetics (D.G.R.E.), St. Mary's Hospital, Manchester, UK.
Address correspondence and reprint requests to Dr. Michael E. Baser, 10622 Kinnard Avenue, #203, Los Angeles, CA 90024; e-mail: michael.baser{at}verizon.net
Diagnostic criteria for schwannomatosis have been proposed in a recent consensus statement. These criteria permit schwannomatosis to be distinguished from neurofibromatosis type 2 (NF2) in most patients, but there is some clinical overlap between the two diseases. In this study, the authors use data from the population-based United Kingdom NF2 Registry to recommend modifications that increase the specificity of the schwannomatosis diagnostic criteria.
Disclosure: The authors report no conflicts of interest.
Received July 14, 2005. Accepted in final form December 1, 2005.
This article has been cited by other articles:
![]() |
K D Hadfield, W G Newman, N L Bowers, A Wallace, C Bolger, A Colley, E McCann, D Trump, T Prescott, and D G R Evans Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis J. Med. Genet., June 1, 2008; 45(6): 332 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. DeSantis, E. A. Houseman, B. A. Coull, A. Stemmer-Rachamimov, and R. A. Betensky A penalized latent class model for ordinal data Biostat., April 1, 2008; 9(2): 249 - 262. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |